What are alternative management options for tremor in Parkinson's disease?

Alternative Tremor Management Options for Parkinson's Disease

For Parkinson's tremor inadequately controlled by oral medications, deep brain stimulation (DBS) targeting the subthalamic nucleus (STN) or globus pallidus internus (GPi) is the primary invasive therapy, with MRI-guided focused ultrasound (MRgFUS) of the STN serving as an alternative for patients with asymmetric, predominantly unilateral tremor. 1

Invasive Therapies for Tremor-Dominant PD

Deep Brain Stimulation (DBS)

STN-DBS and GPi-DBS are equally effective for tremor reduction and should be considered first-line invasive options when oral medications fail to adequately control tremor 1. Both targets effectively reduce tremor severity, but there are important distinctions:

• STN-DBS is uniquely reported to control dopamine-resistant tremor, making it particularly valuable when tremor persists despite adequate levodopa response in other motor symptoms 1
• GPi-DBS may be preferred if there are concerns about cognitive decline (particularly processing speed and working memory) or depression risk 2
• Both targets influence other PD motor symptoms beyond tremor, providing comprehensive motor benefit 1
• Long-term efficacy is well-established, with sustained benefit beyond 15 years 1

MRI-Guided Focused Ultrasound (MRgFUS)

STN-MRgFUS achieves up to 92% tremor reduction unilaterally and represents an alternative for specific patient populations 1:

Best candidates for MRgFUS:

• Tremor-dominant PD with asymmetric, predominantly unilateral presentation
• Elderly patients with multimorbidity who cannot tolerate DBS surgery
• Patients seeking incisionless intervention

Critical limitations:

• Evidence based on only 1 RCT with limited long-term data (3 years vs. 15+ years for DBS)
• DBS should be preferred in younger patients because it allows adaptation to disease progression through parameter adjustments 1
• Cannot be adjusted after the procedure (permanent lesion)

VIM-MRgFUS is NOT recommended for PD tremor in patients with life expectancy of decades, as it lacks sufficient effect on akinesia and rigidity 1

Pharmacological Alternatives

When Oral Medications Are Insufficient

Levodopa remains the most efficacious first-line treatment for PD tremor, though response can be variable 3. When tremor persists despite levodopa optimization:

Adjunctive medications to consider:

1. Propranolol - May improve both resting and action tremor as an adjunct to levodopa 3

2. Clozapine - Can be considered for refractory tremor, but has an unfavorable adverse effect profile requiring regular blood monitoring 3

3. Anticholinergics - Generally lower antitremor efficacy than levodopa, limited to young, cognitively intact patients due to adverse effects 3

4. Dopamine agonists - No evidence of greater antitremor efficacy compared to levodopa, though some targeting D2 receptors offer notable tremor reduction 4, 3

Continuous Medication Delivery Systems

For patients with off-period tremor episodes:

• Levodopa-carbidopa intestinal gel (LCIG) via percutaneous ileostomy
• Continuous subcutaneous apomorphine infusion
• On-demand treatments: subcutaneous/sublingual apomorphine, inhaled levodopa 3

However, there is limited evidence specifically supporting LCIG or continuous apomorphine infusion (CAI) for orally insufficiently treated PD tremor 1

Clinical Decision Algorithm

For Young Patients (<60 years) with Tremor

1. Optimize levodopa therapy first
2. If tremor persists and is medically refractory → STN-DBS or GPi-DBS (allows future adaptation to disease progression)
3. Consider adjunctive propranolol or clozapine if surgery not desired/feasible

For Elderly Patients with Tremor

1. Optimize levodopa therapy
2. If surgical candidate and tremor refractory → STN-DBS or GPi-DBS
3. If NOT surgical candidate (multimorbidity, cognitive impairment, high surgical risk) → VIM-MRgFUS for predominantly unilateral tremor 1
4. Pharmacological adjuncts as above

For Patients with Asymmetric, Unilateral Tremor

STN-MRgFUS can be considered within clinical registries 1, particularly if:

• Patient prefers incisionless approach
• Tremor is distinctly unilateral
• Patient understands limited long-term data

Critical Pitfalls to Avoid

Do not target VIM (ventro-intermediate thalamus) in younger PD patients - While VIM stimulation reduces tremor, it does not address other PD motor symptoms (akinesia, rigidity), making it unsuitable for patients with decades of life expectancy 1

Assess for gait impairment before DBS - Patients with preexisting gait problems (peripheral neuropathy, orthopedic causes, PD-related gait dysfunction) may experience worsening after DBS 1

Consider cognitive and mood factors in target selection - If significant concerns exist about cognitive decline or depression, GPi-DBS is preferred over STN-DBS 2

Medication review is crucial - Ensure tremor is not medication-induced before pursuing invasive therapies 4